CONTACT US
Search
Close this search box.

Podcasts

© Podcasts created using Google NotebookLM.

Podcast about Syqe's #6 clinical study that deals with the differences between men and women in the effectiveness and safety of treatment using the SyqeAir Inhaler

Evaluating Sex Differences in Efficacy, Safety and Pharmacokinetics in Patients Treated with Cannabis by a Metered-Dose Inhaler

Syqe®’s 2023 study evaluated sex differences in effectiveness, safety, and pharmacokinetics of medical cannabis treatment delivered via the metered-dose SyqeAir Inhaler under real-world conditions. Listen to the podcast.
Podcast about Syqe's #4 clinical study that deals with the long-term effectiveness and safety of treatment using the SyqeAir Inhaler

Long-Term Effectiveness and Safety of Medical Cannabis Administered through the Metered-Dose SyqeAir Inhaler

Syqe®’s 2022 PAIN Reports study examined the long-term effectiveness and safety of medical cannabis treatment delivered via the metered-dose SyqeAir Inhaler under real-world conditions. Listen to the podcast.

The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial

Syqe®’s third study (2020) evaluated the SyqeAir Inhaler as a solution for safe, consistent, and low-dose medical cannabis treatment in patients with chronic neuropathic pain. Listen to the podcast.

Evaluation of the Ease of Use, Effectiveness, Safety, and Satisfaction of the SyqeAir Inhaler for Medical Cannabis Treatment Among Hospitalized Patients and Medical Staff

Syqe®’s second study (2019) examined the use of the SyqeAir Inhaler for medical cannabis administration in hospitals to allow patients to maintain their treatment regimen also during hospitilizations. Listen to the podcast.

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of the SyqeAir Metered-Dose Cannabis Inhaler for Chronic Neuropathic Pain: A Phase 1a Study

Syqe®’s first study (2014) examined whether metered and low doses of Δ9-THC allow for dose-dependent pain reduction of chronic neuropathic pain without significant adverse events. Listen to the podcast.
Medical Cannabis
SyqeAir Inhaler
Useful Information
Media
Contact Syqe®

Phone. +972-3-376-7338
Email. info@syqemed.com
Syqe® Israel. syqe.co.il

Show Us Some Love

SyqeAir logo white
The site and the content therein are provided for general knowledge only and do not constitute advertising and/or medical, pharmacological, or professional advice, diagnosis, treatment, or other healthcare services that in any way generate a doctor-patient relationship and/or recommendation for treatment or products in general, and for medical cannabis products and/or SyqeAir inhaler in particular. You should make all medical or health-related decisions on the basis of professional advice from a licensed physician or qualified healthcare professional who is fully aware of your individual circumstances. For any questions regarding products, including medical cannabis products and/or the SyqeAir inhaler, please consult your attending physician and/or the pharmacist at the dispensing pharmacy. The use and reliance on all content appearing on this site are at your sole responsibility, and Syqe® will not be responsible for any decision or action taken by you as a result of relying on this site.
Skip to content